New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
09:07 EDTPWRD, CYTX, RAX, ARO, BHP, PDLI, RDEN, HD, ONTY, JMEI, SKH, DKSOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Home Depot (HD), up 3.8%... Aeropostale (ARO), up 12%... Dick's Sporting (DKS), up 5.3%... PDL BioPharma (PDLI), up 5.7%. HIGHER: Skilled Healthcare (SKH), up 27.2% after combining with Genesis HealthCare In 100% stock deal... Cytori Therapeutics (CYTX), up 8% after BARDA executes contract option with the company valued at $12.1M... Rackspace (RAX), up 3.2% after Blue Harbour reported a 6.4% stake in the company. DOWN AFTER EARNINGS: Elizabeth Arden (RDEN), down 23.3%... Jumei (JMEI), down 3.5%... Perfect World (PWRD), down 2.4%. LOWER: Oncothyreon (ONTY), down 14.4% after announcing that EMR 63325-009 study did not its meet primary endpoint... BHP Billiton (BHP), down 3% after announcing the demerger of its metals and mining company to be completed in 1H15...
News For HD;ARO;DKS;RDEN;RAX;SKH;PDLI;CYTX;JMEI;BHP;PWRD;ONTY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
November 11, 2014
08:42 EDTRAXRackspace buyback likely to push shares higher, says Needham
Subscribe for More Information
08:13 EDTRAXRackspace reported strong Q3 results, says Oppenheimer
Oppenheimer believes that Rackspace's Q3 results showed very strong trends, and it thinks the company's revenue/EBITDA growth can reach high teen percentage levels in 2015-2016. The firm keeps a $62 price target and Outperform rating on the shares.
07:51 EDTRAXRackspace price target raised to $50-$52 from $42-$46 at Wells Fargo
Subscribe for More Information
07:49 EDTARO, DKSBofA/Merrill retail and consumer analysts hold analyst/industry conference call
Subscribe for More Information
07:09 EDTHDHome Depot November volatility elevated into Q3 and revenue outlook
Home Depot November call option implied volatility is at 24, December is at 20, January is at 18; compared to its 26-week average of 18 according to Track Data, suggesting large near term price movement into the expected release of Q3 results on November 18.
November 10, 2014
18:32 EDTRAXOn The Fly: After Hours Movers
Subscribe for More Information
17:10 EDTRAXRackspace CEO says buyback an example of confidence in future
Subscribe for More Information
17:08 EDTRAXRackspace CEO says management 'feels good' about Q4 pipeline
16:50 EDTRAXRackspace CEO says company is committed to revenue growth, margin
Comments provided during Q3 earnings conference call.
16:42 EDTRAXRackspace up 2% to $38 after Q3 results, $500M share buyback
16:40 EDTRAXRackspace says joined Microsoft Cloud OS Network
Rackspace (RAX) said it expanded its Managed Private Cloud product portfolio and joined the Microsoft (MSFT) Cloud OS Network, adding Fanatical Support for the Microsoft Cloud Platform. It stated, "This includes expertise and support for Windows Server with Hyper-V, System Center and Azure Pack. The offering is now in general availability in all U.S. data centers providing customers with SLA-backed management across the underlying infrastructure, guest operating systems, and select applications including Microsoft Exchange, SharePoint and Lync."
16:39 EDTRAXRackspace says Q4 revenue outlook includes negative FX impact
Subscribe for More Information
16:37 EDTRAXRackspace announces $500M share repurchase plan
Subscribe for More Information
16:28 EDTONTYOncothyreon, Celldex announce initiation of ONT-10, varlilumab clinical trial
Oncothyreon Inc. (ONTY) and Celldex Therapeutics (CLDX) announced that they have initiated a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. The trial is an open-label Phase 1b study of ONT-10 administered at the recommended single agent dose in combination with varlilumab at two dose levels in up to 42 patients with advanced breast or ovarian cancer. The primary objective of the trial is to determine the safety and tolerability of the combined therapy. Additional objectives include evaluations of the impact of combination treatment on MUC1-specific humoral and cellular immune responses, T-cell activation markers and levels of regulatory T-cells, and anti-tumor effects. The Phase 1b trial will be conducted by Oncothyreon under the terms of a previously announced collaboration agreement between Oncothyreon and Celldex. The two companies will jointly own the data from the trial and will make any plans for potential future development of the combination therapy together. Under the agreement, neither company has granted the other a license, or any other rights, to its product candidate.
16:11 EDTPDLIPDL BioPharma reports Q3 EPS 61c, consensus 56c
Subscribe for More Information
16:10 EDTRAXRackspace sees Q4 adjusted EBITDA margin 33%-35%
16:09 EDTRAXRackspace sees Q4 EPS $469M-$476M , consensus 476.51M
Subscribe for More Information
16:08 EDTRAXRackspace reports Q3 EPS 18c, consensus 16c
Subscribe for More Information
15:26 EDTRAXNotable companies reporting after market close
Subscribe for More Information
13:47 EDTRAXRackspace technical comments before earnings
The shares have broadly outperformed in the prior three months, trading up over 16%. Since a bearish gap down in September, the stock has been trending up. A look at a 1-year chart shows the importance of the $40 level. It has been touched as resistance several times over that interval, but without being able to break through for long. On stronger than expected news, a move to the $40 area would seem probable. If the news or outlook is sufficiently strong, there could be a breakout above $40. Such a breakout given the length of time the $40 area has been resistance would be long-term bullish for price. Additional upside objectives above $40 would be at $42.09 and then at $43.83. If the news is worse than expected, there are several points of support that could be tested as downside objectives: $34.70, $32.36, and $30.74. A move down through all of the levels noted would retrace the advance made in recent months nearly completely.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use